Why Is NEOGEN CORP (NEOG) Stock Down Today?

NEOG stock closed down 7.22% at $12.73 on Friday, marking a sharp decline driven by an FDA warning letter issued to Neogen Corp. The letter relates to its veterinary product Hycoat, which has been linked to a large number of horse deaths. The agency cited contamination of the product, which is marketed as a sterile wound management solution.

What Happened

The FDA issued a warning letter to Neogen following an investigation that linked contamination of Hycoat to a significant number of horse deaths. The agency stated that the contamination was associated with the largest number of deaths in horses tied to a product quality defect in any FDA-regulated veterinary medical product. The warning letter has led to a sell-off in the stock, with shares falling sharply in response. Guggenheim analysts have called the selloff "overdone," while some traders are circulating an unconfirmed analyst report defending the company, noting that Hycoat is third-party manufactured and that the revenue impact is immaterial. The CEO, Nassif Mikheal, has remained active in the market, with recent insider filings showing purchases totaling $4,000 in the last 90 days.

What The Data Shows

NEOG has a market cap of $3.0 billion and remains unprofitable, with a trailing twelve-month EPS of -0.04 and a net margin of -0.9%. The stock has a beta of 1.76, indicating above-average volatility. On Friday, it hit a fresh 52-week low, adding to 24 such instances on the year. The stock has traded between $5.32 and $14.26 over the past 52 weeks. The recent insider purchases suggest continued confidence from management, though the stock remains under pressure from the FDA-related concerns.

What To Watch

Neogen is expected to report first-quarter earnings soon. Investors will be watching for any updates on the Hycoat situation, including the status of FDA discussions and the potential impact on revenue. Coverage breadth and analyst reactions will also be key in assessing the stock’s near-term trajectory.